Programmed death ligand‐1 expression is associated with poor disease free survival in salivary gland carcinomas

Abstract

Positive PD-L1 expression was significantly associated with poor disease free survival of SGCs, suggesting that antibody therapies targeting PD-1/PD-L1 may have potential application in SGCs. J. Surg. Oncol. 2016;114:36-43. © 2016 Wiley Periodicals, Inc.

Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis

“…Seventeen studies were included in the meta-analysis, among which nine studies [19, 21, 23, 29–34] investigated HNC patients from Asian countries/regions (including China, Japan, Korea, Taiwan and Hong Kong), five studies [5, 20, 22, 24, 38] investigated patients from European countries (including Germany, France and Greece), and three studies [35–37] investigated patients from other countries (USA, Australia and Brazil). The studies were published between 2011 and 2016, and the number of HNC patients they included ranged from 23 to 517.…”

“…Four studies included patients diagnosed with head and neck squamous cell carcinoma (HNSCC) [5, 22–24] while the remaining studies included patients diagnosed with the subtypes of HNC: six studies included patients with oral squamous cell carcinoma (OSCC) [19, 20, 29, 33, 35, 36], three studies included patients with nasopharyngeal carcinoma (NPC) [21, 30, 32], two studies included patients with oropharyngeal squamous cell carcinoma (OPSCC) [31, 37], one study included patients with laryngeal squamous cell carcinoma (LSCC) [38], and one study included patients with salivary gland carcinoma (SGC) [34]. Fourteen studies [5, 19, 20, 22, 23, 29, 31–38] showed the data of OS, and 11 studies [19–22, 24, 30–32, 34, 36, 38] showed the data of DFS. HRs with 95% CIs were obtained from the reports in ten studies [5, 19, 22, 23, 31–35, 38], and calculated from available data in seven studies [20, 21, 24, 29, 30, 36, 37].…”

“…HRs with 95% CIs were obtained from the reports in ten studies [5, 19, 22, 23, 31–35, 38], and calculated from available data in seven studies [20, 21, 24, 29, 30, 36, 37]. Fourteen studies [5, 20–24, 29–33, 35–37] provided the survival data calculated by univariate analysis, two studies [19, 34] provided the data calculated by multivariate analysis, and one study [38] provided both the data calculated by univariate analysis and by multivariate analysis.…”

“…Eleven studies [19–22, 24, 30–32, 34, 36, 38] provided the data of DFS, but significant heterogeneity existed among these studies ( I 2 = 73.1%, P < 0.001). Therefore, a random-effects model was applied to pool the data.…”

Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy

“…While this mutational burden is higher than that of other salivary tumors such as adenoid cystic carcinoma [49], it is far lower than that of other cancer types that respond well to immunotherapy, such as colorectal cancer, lung cancer or melanoma [83]. However, a recent study demonstrated that the immune checkpoint ligand programmed death ligand 1 (PD-L1) was expressed in nearly half of 31 SDC specimens, suggesting that anti-PD-1/PD-L1 or other checkpoint inhibitors may have some anti-tumor activity in this disease [84]. Pembrolizumab, an anti-PD1 antibody, showed 11.5% response rate and 46.2% stable disease rate in a small expansion cohort of 26 advanced salivary gland cancer patients – 2 out of 3 responders had SDC [85].…”